Physician profile
Robert Baker
NPI 1205896503
$1,073.92
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $181 · 2021: $173 · 2022: $418 · 2023: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $204.13 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $151.12 | 2020-2022 | |
| Abbvie INC. | $84.61 | 2022-2023 | Vraylar |
| Astellas Pharma US INC | $62.79 | 2020-2022 | |
| Novo Nordisk INC | $52.87 | 2019-2022 | |
| Pfizer INC. | $49.16 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $48.14 | 2019-2020 | |
| Lilly USA, LLC | $39.26 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.95 | 2022 | |
| Amgen INC. | $36.36 | 2019-2023 | Repatha, Otezla |
| Daiichi Sankyo INC. | $34.50 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.19 | 2022 | |
| Glaxosmithkline, LLC. | $30.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.29 | 2022 | |
| Tactile Systems Technology INC | $27.97 | 2022-2023 | Entre Plus, Flexitouch Plus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.00 | 2019-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $23.11 | 2021-2022 | |
| Axsome Therapeutics, INC. | $22.26 | 2023 | Auvelity |
| Abbott Laboratories | $16.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.65 | 2020 | |
| Esperion Therapeutics, INC. | $14.28 | 2021 | |
| Dynavax Technologies Corporation | $14.01 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $12.16 | 2022 | |
| Hikma Pharmaceuticals USA | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.